Article Details

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 ... - PR Newswire

Retrieved on: 2022-10-28 00:28:58

Tags for this article:

Click the tags to see associated articles and topics

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 ... - PR Newswire. View article details on HISWAI: https://www.prnewswire.com/news-releases/q32-bio-and-horizon-therapeutics-plc-announce-dosing-of-first-patient-in-phase-2-trial-of-adx-914-for-atopic-dermatitis-301661137.html

Excerpt

"ADX-914 represents a potential unique approach to correcting immune system dysregulation," said Elizabeth H.Z. Thompson, Ph.D., Executive Vice ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up